fda semaglutide compounding news The FDA's Decision to Ban Compounds: What You Need to Know The End of Compounded Semaglutide:

Its evident that while Ozempic has offered some benefits, Novo Nordisk has failed in its duty to adequately warn and protect patients, highlighting the urgent need for legal action to hold them accountable for the widespread injuries suffered

Sources & further reading TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial New England Journal of Medicine (Jastreboff et al., 2023), 2023 FDA's concerns with unapproved GLP-1 drugs used for weight loss (grey-market copies) U.S

Flexible Spending Accounts (FSAs) can cover FDA-approved GLP-1 receptor agonists, and PlexusDx compounded medications qualify under this category

Start on hands and knees

Another thing that's fascinating about the GLP-1 is its effect on epigenetic clocks